Paper Details
- Home
- Paper Details
Incidence of steroid-induced ocular hypertension after vitreoretinal surgery with difluprednate versus prednisolone acetate.
Author: ConnorsDaniel B, FineHoward F, JengKaren W, PrennerJonathan L, RothDaniel, WheatleyH Matthew
Original Abstract of the Article :
PURPOSE: To identify changes in intraocular pressure (IOP) after vitreoretinal surgical procedures in eyes that received either difluprednate ophthalmic emulsion 0.05% (DP) or prednisolone acetate ophthalmic suspension 1% (PA). METHODS: A retrospective chart review compared a consecutive series of ...See full text at original site
Dr.Camel's Paper Summary Blogラクダ博士について
ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。
* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。
引用元：
https://doi.org/10.1097/IAE.0000000000000215
データ提供：米国国立医学図書館（NLM）
Ocular Hypertension After Vitreoretinal Surgery: A Comparison of Difluprednate and Prednisolone Acetate
This study investigates the incidence of steroid-induced ocular hypertension following vitreoretinal surgery in patients receiving either difluprednate or prednisolone acetate. The researchers conducted a retrospective chart review to compare the IOP changes in two groups of patients treated with these medications. The study highlights the increased risk of ocular hypertension associated with difluprednate compared to prednisolone acetate, emphasizing the need for careful monitoring of IOP in patients receiving difluprednate.
Difluprednate: A Potential Risk for Ocular Hypertension
The study reveals that difluprednate is associated with a significantly higher risk of developing ocular hypertension compared to prednisolone acetate following vitreoretinal surgery. This finding underscores the importance of vigilant IOP monitoring in patients receiving difluprednate to mitigate the risk of this complication. The study's findings provide valuable insights into the ophthalmic side-effect profile of difluprednate, informing clinical decision-making and optimizing patient care.
Navigating Ophthalmic Treatments: A Journey Towards Safe Vision
This research emphasizes the need for careful consideration of the potential risks and benefits of different ophthalmic medications. It highlights the importance of vigilant IOP monitoring in patients receiving difluprednate, ensuring the safety and preservation of vision following vitreoretinal surgery. This journey through the complexities of ophthalmic treatments can lead to more informed decisions and safer outcomes for patients.
Dr.Camel's Conclusion
This study reveals the increased risk of ocular hypertension associated with difluprednate compared to prednisolone acetate following vitreoretinal surgery. The research emphasizes the need for vigilant IOP monitoring in patients receiving difluprednate to ensure the safety and preservation of vision. This research is like a compass guiding us through the complexities of ophthalmic treatments, navigating the potential risks and benefits of different medications to achieve the best possible outcomes for patients.
Date :
- Date Completed 2015-03-05
- Date Revised 2022-03-11
Further Info :
Related Literature
English
This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.